ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 185-192

  Mahajan, Kiran ^a   Mahajan, Nupam P ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ACK1; AKT; Drug resistance; Small molecule inhibitor; TNK2; Tyrosine kinase

Indexed keywords

1,3 DITHIOLANE SUBSTITUTED PYRROLOPYRIMIDINE; 2,3 DIPHENYL N ((TETRAHYDROFURAN 2 YL)METHYL)FURO[2,3 B]PYRIDIN 4 AMINE; 4 AMINO 5,6 BIARYL FURO[2,3 D]PYRIMIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DASATINIB; IMIDAZO[1,5 A]PYRAZINE DERIVATIVE; N3,N6 DIARYL 1H PYRAZOLO[3,4 D]PYRIMIDINE 3,6 DIAMINE DERIVATIVE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE ACK1; PYRIMIDO BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG; VEMURAFENIB;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STABILITY; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ACK1; AKT; DRUG RESISTANCE; SMALL MOLECULE INHIBITOR; TNK2; TYROSINE KINASE;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84881668744     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.004     Document Type: Review

References (71)

1. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
2. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934. (New York, NY).
3. Xiao A., Li H., Shechter D., Ahn S.H., Fabrizio L.A., Erdjument-Bromage H., Ishibe-Murakami S., Wang B., Tempst P., Hofmann K., Patel D.J., Elledge S.J., Allis C.D. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature 2009, 457:57-62.
4. Broekman F., Giovannetti E., Peters G.J. Tyrosine kinase inhibitors: multi-targeted or single-targeted?. World Journal of Clinical Oncology 2011, 2:80-93.
5. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annual Review of Pharmacology and Toxicology 2013, 53:161-185.
6. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
7. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 2006, 3:448-457.
8. Zhang L., Daly R.J. Targeting the human kinome for cancer therapy: current perspectives. Critical Reviews in Oncogenesis 2012, 17:233-246.
9. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Review Clinical Oncology 2012, 9:16-32.
10. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research 2005, 65:2412-2421.
11. Mahajan K., Mahajan N.P. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. Journal of Cellular Physiology 2010, 224:327-333.
12. Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Research 2005, 65:10514-10523.
13. Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., Earp H.S., Whang Y.E. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8438-8443.
14. Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., Schonbrunn E., Sebti S.M., Earp H.S., Mahajan N.P. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS ONE 2010, 5:e9646.
15. Prieto-Echague V., Miller W.T. Regulation of ack-family nonreceptor tyrosine kinases. Journal of Signal Transduct 2011, 2011:742372.
16. Pao-Chun L., Chan P.M., Chan W., Manser E. Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. The Journal of Biological Chemistry 2009.
17. Lin Q., Wang J., Childress C., Yang W. The activation mechanism of ACK1 (activated Cdc42-associated tyrosine kinase 1). Biochemical Journal 2012, 445:255-264.
18. Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 2010, 70:1274-1285.
19. Mahajan K., Coppola D., Chen Y.A., Zhu W., Lawrence H.R., Lawrence N.J., Mahajan N.P. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. American Journal of Pathology 2012, 180:1386-1393.
20. Mahajan K., Coppola D., Rawal B., Chen Y.A., Lawrence H.R., Engelman R.W., Lawrence N.J., Mahajan N.P. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. The Journal of Biological Chemistry 2012, 287:22112-22122.
21. Prieto-Echague V., Gucwa A., Brown D.A., Miller W.T. Regulation of Ack1 localization and activity by the amino-terminal SAM domain. BMC Biochemistry 2010, 11:42.
22. Gajiwala K.S., Maegley K., Ferre R., He Y.A., Yu X. Ack1: activation and regulation by allostery. PLoS ONE 2013, 8:e53994.
23. Prieto-Echague V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. The Journal of Biological Chemistry 2010, 285:10605-10615.
24. Chua B.T., Lim S.J., Tham S.C., Poh W.J., Ullrich A. Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Molecular Oncology 2010, 4:323-334.
25. Ruhe J.E., Streit S., Hart S., Wong C.H., Specht K., Knyazev P., Knyazeva T., Tay L.S., Loo H.L., Foo P., Wong W., Pok S., Lim S.J., Ong H., Luo M., Ho H.K., Peng K., Lee T.C., Bezler M., Mann C., Gaertner S., Hoefler H., Iacobelli S., Peter S., Tay A., Brenner S., Venkatesh B., Ullrich A. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Research 2007, 67:11368-11376.
26. Mahajan K., Mahajan N.P. PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics. Journal of Cell Physiology 2012, 227:3178-3184.
27. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., Asangani I.A., Ateeq B., Chun S.Y., Siddiqui J., Sam L., Anstett M., Mehra R., Prensner J.R., Palanisamy N., Ryslik G.A., Vandin F., Raphael B.J., Kunju L.P., Rhodes D.R., Pienta K.J., Chinnaiyan A.M., Tomlins S.A. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
28. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Research 2003, 63:3877-3882.
29. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
30. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
31. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., Ekman P., DeMarzo A.M., Tibshirani R., Botstein D., Brown P.O., Brooks J.D., Pollack J.R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:811-816.
32. van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L., Orf J., Rong M., Li S., See L.H., Nguyen K.Q., Hoey T., Wesche H., Powers S. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15901-15906.
33. Zupa A., Improta G., Silvestri A., Pin E., Deng J., Aieta M., Musto P., Nitti D., Mammano E., Liotta L., Belluco C., Wulfkuhle J., Petricoin E. A pilot characterization of human lung NSCLC by protein pathway activation mapping. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 2012, 7:1755-1766.
34. Saydam O., Senol O., Wurdinger T., Mizrak A., Ozdener G.B., Stemmer-Rachamimov A.O., Yi M., Stephens R.M., Krichevsky A.M., Saydam N., Brenner G.J., Breakefield X.O. MiRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Research 2011, 71:852-861.
35. MacKeigan J.P., Murphy L.O., Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biology 2005, 7:591-600.
36. Schoenherr J.A., Drennan J.M., Martinez J.S., Chikka M.R., Hall M.C., Chang H.C., Clemens J.C. Drosophila activated Cdc42 kinase has an anti-apoptotic function. PLoS Genetics 2012, 8:e1002725.
37. Jose A.M., Kim Y.A., Leal-Ekman S., Hunter C.P. Conserved tyrosine kinase promotes the import of silencing RNA into Caenorhabditis elegans cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:14520-14525.
38. Lougheed J.C., Chen R.H., Mak P., Stout T.J. Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1. The Journal of Biological Chemistry 2004, 279:44039-44045.
39. Kastan M.B. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes memorial award lecture. Molecular Cancer Research 2008, 6:517-524.
40. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
41. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nature Reviews Cancer 2003, 3:155-168.
42. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., 3rd, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166. (New York, NY).
43. Tiedemann R.E., Zhu Y.X., Schmidt J., Yin H., Shi C.X., Que Q., Basu G., Azorsa D., Perkins L.M., Braggio E., Fonseca R., Bergsagel P.L., Mousses S., Stewart A.K. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010, 115:1594-1604.
44. Pal S.K., Reckamp K., Yu H., Figlin R.A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs 2010, 19:1355-1366.
45. Chan W., Tian R., Lee Y.F., Sit S.T., Lim L., Manser E. Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2. The Journal of Biological Chemistry 2009, 284:8185-8194.
46. Lin Q., Wang J., Childress C., Sudol M., Carey D.J., Yang W. HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK. Molecular and Cellular Biology 2010, 30:1541-1554.
47. Grovdal L.M., Johannessen L.E., Rodland M.S., Madshus I.H., Stang E. Dysregulation of Ack1 inhibits down-regulation of the EGF receptor. Experimental Cell Research 2008, 314:1292-1300.
48. Nishimura Y., Bereczky B., Ono M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochemistry and Cell Biology 2007, 127:541-553.
49. Buchwald M., Pietschmann K., Brand P., Gunther A., Mahajan N.P., Heinzel T., Kramer O.H. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. Oncogene 2012.
50. DiMauro E.F., Newcomb J., Nunes J.J., Bemis J.E., Boucher C., Buchanan J.L., Buckner W.H., Cheng A., Faust T., Hsieh F., Huang X., Lee J.H., Marshall T.L., Martin M.W., McGowan D.C., Schneider S., Turci S.M., White R.D., Zhu X. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. Bioorganic and Medicinal Chemistry Letters 2007, 17:2305-2309.
51. Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G., Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H., Kayser F. Identification and optimization of N3, N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2008, 18:6352-6356.
52. Miduturu C.V., Deng X., Kwiatkowski N., Yang W., Brault L., Filippakopoulos P., Chung E., Yang Q., Schwaller J., Knapp S., King R.W., Lee J.D., Herrgard S., Zarrinkar P., Gray N.S. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chemistry and Biology 2011, 18:868-879.
53. Jiao X., Kopecky D.J., Liu J., Liu J., Jaen J.C., Cardozo M.G., Sharma R., Walker N., Wesche H., Li S., Farrelly E., Xiao S.H., Wang Z., Kayser F. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2012, 22:6212-6217.
54. Jin M., Wang J., Kleinberg A., Kadalbajoo M., Siu K.W., Cooke A., Bittner M.A., Yao Y., Thelemann A., Ji Q., Bhagwat S., Mulvihill K.M., Rechka J.A., Pachter J.A., Crew A.P., Epstein D., Mulvihill M.J. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2013, 23:979-984.
55. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
56. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., Borzilleri R.M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry 2004, 47:6658-6661.
57. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11011-11016.
58. Li J., Rix U., Fang B., Bai Y., Edwards A., Colinge J., Bennett K.L., Gao J., Song L., Eschrich S., Superti-Furga G., Koomen J., Haura E.B. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chemical Biology 2010, 6:291-299.
59. Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010, 29:3208-3216.
60. Phatak S.S., Zhang S. A novel multi-modal drug repurposing approach for identification of potent ack1 inhibitors. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2013, 29-40.
61. Bogoyevitch M.A., Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today 2007, 12:622-633.
62. Fischer P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry 2004, 11:1563-1583.
63. Iacob R.E., Zhang J., Gray N.S., Engen J.R. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS ONE 2011, 6:e15929.
64. Cox K.J., Shomin C.D., Ghosh I. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Medicinal Chemistry 2011, 3:29-43.
65. Eglen R.M., Reisine T. Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors. Expert Opinion on Drug Discovery 2010, 5:277-290.
66. Eglen R., Reisine T. Drug discovery and the human kinome: Recent trends. Pharmacology and Therapeutics 2011, 130:144-156.
67. Annis D.A., Nickbarg E., Yang X., Ziebell M.R., Whitehurst C.E. Affinity selection-mass spectrometry screening techniques for small molecule drug discovery. Current Opinion in Chemical Biology 2007, 11:518-526.
68. Muckenschnabel I., Falchetto R., Mayr L.M., Filipuzzi I. SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. Analytical Biochemistry 2004, 324:241-249.
69. Zehender H., le Goff F., Lehmann N., Filipuzzi I., Mayr L.M. Speedscreen: the "missing link" between genomics and lead discovery. Journal of Biomolecule Screening 2004, 9:498-505.
70. Comess K.M., Schurdak M.E. Affinity-based screening techniques for enhancing lead discovery. Current Opinion Drug Discovery Device 2004, 7:411-416.
71. Comess K.M., Trumbull J.D., Park C., Chen Z., Judge R.A., Voorbach M.J., Coen M., Gao L., Tang H., Kovar P., Cheng X., Schurdak M.E., Zhang H., Sowin T., Burns D.J. Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1. Journal of Biomolecule Screening 2006, 11:755-764.